PeerView Internal Medicine CME/CNE/CPE Video Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

http://ww2.peerview.com

subscribe
share





Lisa H. Lancaster, MD - How I Think, How I Treat – Contemporary Insights on Diagnosing and Managing SSc-ILD in an Evolving Treatment Landscape


Go online to PeerView.com/RUB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis is a rare connective-tissue disease that affects multiple organ systems and is characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Interstitial lung disease occurs in most patients with SSc and is now the primary cause of death in these patients. Treatment for SSc-ILD has historically been limited; however, novel therapies are now available and in development. At a recent live web broadcast, a panel of expert faculty offered insight to help clinicians achieve a greater understanding of the recognition, diagnosis, and management of SSc-ILD, including the latest clinical evidence on novel and emerging therapies. If you couldn't watch the live event, catch up with this on-demand version. Upon completion of this activity, participants should be better able to: Identify signs and symptoms of systemic sclerosis in patients initially presenting with clinical features indicative of interstitial lung disease, Discuss the importance of a multidisciplinary approach in the differential diagnosis and staging of SSc-ILD, Summarize the latest clinical efficacy and safety data on emerging therapies for SSc-ILD, including antifibrotic agents, Apply updated evidence-based recommendations for diagnosis, risk assessment, monitoring, and management of SSc-ILD.


share







 2020-10-09  1h2m